Abstract
THE normal cellular homologue of the acutely transforming oncogene v-ra/is c-raf-l, which encodes a serine/threonine protein kinase that is activated by many extracellular stimuli1. The physiological substrates of the protein c-Raf-1 are unknown. The mitogen-activated protein (MAP) kinases ErkI and 2 are also activated by mitogens through phosphorylation of Erk tyrosine and threonine residues catalysed by a protein kinase of relative molecular mass 50,000, MAP kinase-kinase (MAPK-K)2–7. Here we report that MAPK-K as well as Erkl and 2 are constitutively active in v-raf-transformed cells. MAPK-K partially purified from v-raf-transformed cells or from mitogen-treated cells3 can be deactivated by phosphatase 2A. c-Raf-1 purified after mitogen stimulation can reactivate the phosphatase 2A-inactivated MAPK-K over 30-fold in vitro. c-Raf-1 reactivation of MAPK-K coincides with the selective phosphorylation at serine/threonine residues of a polypeptide with Mr 50,000 which coelutes precisely on cation-exchange chromatography with the MAPK-K activatable by c-Raf-1. These results indicate that c-Raf-1 is an immediate upstream activator of MAPK-K in vivo. To our knowledge, MAPK-K is the first physiological substrate of the c-raf-l protooncogene product to be identified.
Similar content being viewed by others
References
Rapp, U. R. Oncogene 6, 495–500 (1991).
Ahn, N. G., Weiel, J. E., Chan, C. P. & Krebs, E. G. J. biol. Chem. 265, 11487–11494 (1990).
Kyriakis, J. M., Brautigan, D. L., Ingelbritsen, T. S. & Avruch, J. J. biol. Chem. 266, 10043–10046 (1991).
Anderson, N. G., Maller, J. L., Tonks, N. K. & Sturgill, T. W. Nature 343, 651–653 (1990).
Ahn, N. G., et al. J. biol. Chem. 266, 4220–4227 (1991).
Gomez, N. & Cohen, P. Nature 353, 170–173 (1991).
Allemain, G. L., Her, J.-H., Wu, J., Sturgill, T. W. & Weber, M. J. Molec. cell. Biol. 12, 2222–2229 (1992).
Rapp, U. R., Reynolds, F. H. & Stephenson, J. R. J. Virol. 45, 914–924 (1983).
Matsuda, S. et al. EMBO J. 11, 973–982 (1992).
Pulverer, B. J., et al. Nature 353, 670–674 (1991).
Sturgill, T. W., Ray, L. B., Erikson, E. & Maller, J. L. Nature 334, 715–718 (1988).
Dent, P. et al. Nature 348, 302–308 (1990).
Anderson, N. G. et al. Biochem. J. 277, 573–576 (1991).
Lee, R.-M., Cobb, M. H. & Blackshear, P. J. J. biol. Chem. 267, 1088–1092 (1992).
Downward, J. et al. Nature 346, 719–723 (1990).
Burgering, B. M. et al. EMBO J. 10, 1103–1109 (1991).
Satoh, T., Nakafuku, M., Miyajima, A. & Kaziro, Y. Proc natn. Acad. Sci. U.S.A. 88, 3314–3318 (1991).
Leevers, S. J. & Marshall, C. J. EMBO J. 11, 569–574 (1992).
Bruder, J. T., Heidecker, G. & Rapp, U. R. Genes Dev. 6, 545–556 (1992).
Troppmair, J. et al. Oncogene (in the press).
Grove, J. R., Price, D. J., Goodman, H. M. & Avruch, J. Science 238, 530–533 (1987).
Hsi, E. D. et al. J. Biol. Chem. 264, 10836–10842 (1989).
Kyriakis, J. M. & Avruch, J. J. biol. Chem. 265, 17355–17363 (1990).
Takeda, M. et al. J. biol. Chem. 258, 10455–10463 (1988).
Jones, S. W., Erikson, R. L., Ingebritsen, V. M. & Ingebritsen, T. S. J. biol. Chem. 264, 7747–7753 (1989).
Kyriakis, J. M. & Avruch, J. Biochem. Biophys. Acta 1054, 73–82 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kyriakis, J., App, H., Zhang, Xf. et al. Raf-1 activates MAP kinase-kinase. Nature 358, 417–421 (1992). https://doi.org/10.1038/358417a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/358417a0
- Springer Nature Limited
This article is cited by
-
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Signal Transduction and Targeted Therapy (2023)
-
Insights into cellular behavior and micromolecular communication in urothelial micrografts
Scientific Reports (2023)
-
An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer
Molecular Cancer (2022)
-
CD6-mediated inhibition of T cell activation via modulation of Ras
Cell Communication and Signaling (2022)
-
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Journal of Hematology & Oncology (2020)